Acquis Managing Director Zach Fink joined Dr. Beatrice Anduze-Faris on “The 3 Things with Dr. B” podcast to discuss serendipity, purpose, and humanity.
In a wide-ranging conversation, Zach shared compelling perspectives on organizational transformation, personal growth, and the future of technology. Drawing from his extensive experience working with major healthcare, telecommunications, and consumer goods companies, Zach advocates for a fundamental shift in how we approach both corporate strategy and personal development.
One of Zach’s most impactful insights centers on the relationship between strategy and change. “Most companies are operating off a scorecard and list of transformations, but they’re not looking at how those transformations will work together to help them evolve as a company,” he observes. Rather than viewing transformation as discrete projects with clear endpoints, Zach argues for seeing change as continuous evolution. “We need to get away from the word transformation,” Zach shares. “It assumes a start and end – but change is constant.”
The perspectives Zach shares offer valuable insights for both organizational leaders and individuals seeking to navigate today’s rapidly changing landscape. His emphasis on coordination, continuous evolution, and authentic self-reflection provides a framework for thinking about transformation that goes beyond traditional change management approaches to embrace a more holistic and sustainable vision of progress.
Reach out to the Acquis team
Tags:
AI agents that can read, write, and act across systems are making traditional integration obsolete. The question many firms are now asking: Should we maintain 20 specialized systems when AI agents can deliver comparable capabilities using 5-7 core platforms? The economics increasingly suggest the answer is no.
Read More
At the end of 2025, we were closely monitoring three trends we believed would shape the next phase of biopharma’s operating model changes in 2026: data pipelines, the role of AI in due diligence, and the next-generation value chain. The J.P. Morgan Healthcare Conference offered the first opportunity to pressure-test those assumptions.
Read More
AI could transform exit optimization into systematic value maximization. Pattern recognition across thousands of transactions, predictive analytics for buyer behavior, and dynamic narrative construction could help firms identify the perfect moment, find the right buyers, and position assets for maximum value. This represents opportunity arbitrage at its most critical — applying intelligence to the moment that determines returns.
Read More
AI agents that can read, write, and act across systems are making traditional integration obsolete. The question many firms are now asking: Should we maintain 20 specialized systems when AI agents can deliver comparable capabilities using 5-7 core platforms? The economics increasingly suggest the answer is no.
Read More
At the end of 2025, we were closely monitoring three trends we believed would shape the next phase of biopharma’s operating model changes in 2026: data pipelines, the role of AI in due diligence, and the next-generation value chain. The J.P. Morgan Healthcare Conference offered the first opportunity to pressure-test those assumptions.
Read More
AI could transform exit optimization into systematic value maximization. Pattern recognition across thousands of transactions, predictive analytics for buyer behavior, and dynamic narrative construction could help firms identify the perfect moment, find the right buyers, and position assets for maximum value. This represents opportunity arbitrage at its most critical — applying intelligence to the moment that determines returns.
Read More
